Risk management in the treatment of type 2 diabetes with pioglitazone
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-07-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/risk-management-in-the-treatment-of-type-2-diabetes-with-pioglitazone-a3327 |
| _version_ | 1797936126335385600 |
|---|---|
| author | Giuseppe Derosa Sibilla AT Salvadeo |
| author_facet | Giuseppe Derosa Sibilla AT Salvadeo |
| author_sort | Giuseppe Derosa |
| collection | DOAJ |
| description | Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.Keywords: pioglitazone, diabetes mellitus, glycated hemoglobin, cardiovascular prevention |
| first_indexed | 2024-04-10T18:24:53Z |
| format | Article |
| id | doaj.art-c410b88baeb944b1938c2742260003aa |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:24:53Z |
| publishDate | 2009-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-c410b88baeb944b1938c2742260003aa2023-02-02T06:08:37ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072009-07-012009default5160Risk management in the treatment of type 2 diabetes with pioglitazoneGiuseppe DerosaSibilla AT SalvadeoGiuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.Keywords: pioglitazone, diabetes mellitus, glycated hemoglobin, cardiovascular preventionhttp://www.dovepress.com/risk-management-in-the-treatment-of-type-2-diabetes-with-pioglitazone-a3327 |
| spellingShingle | Giuseppe Derosa Sibilla AT Salvadeo Risk management in the treatment of type 2 diabetes with pioglitazone Diabetes, Metabolic Syndrome and Obesity |
| title | Risk management in the treatment of type 2 diabetes with pioglitazone |
| title_full | Risk management in the treatment of type 2 diabetes with pioglitazone |
| title_fullStr | Risk management in the treatment of type 2 diabetes with pioglitazone |
| title_full_unstemmed | Risk management in the treatment of type 2 diabetes with pioglitazone |
| title_short | Risk management in the treatment of type 2 diabetes with pioglitazone |
| title_sort | risk management in the treatment of type 2 diabetes with pioglitazone |
| url | http://www.dovepress.com/risk-management-in-the-treatment-of-type-2-diabetes-with-pioglitazone-a3327 |
| work_keys_str_mv | AT giuseppederosa riskmanagementinthetreatmentoftype2diabeteswithpioglitazone AT sibillaatsalvadeo riskmanagementinthetreatmentoftype2diabeteswithpioglitazone |